Insights into current coccidioidomycosis therapeutic pathways
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01465-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Brent Edwards und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Coccidioidomycosis, Antifungal Agents, Fluconazole. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F2G (F2G Ltd).
Abstract (Originalsprache)
Coccidioidomycosis is a systemic fungal infection caused by Coccidioides immitis and Coccidioides posadasii , which are endemic to the Southwestern United States and parts of Mexico, Central, and South America. While oral fluconazole is widely recommended as first-line therapy, treatment failure is not uncommon for severe manifestations. This study aims to characterize antifungal treatment pathways, identify factors associated with treatment switches, and compare outcomes based on treatment courses. A retrospective cohort study was conducted using the TriNetX database with individual de-identified clinical data. Using International Classification of Diseases, Tenth Revision, Clinical Modification codes, we identified patients diagnosed with coccidioidomycosis between January 2010 and March 2024. “Treatment switches” were defined as receiving a different antifungal agent for at least three consecutive days after an initial regimen. Patient demographics, comorbidities, hospitalizations, ICU admissions, and mortality were assessed. A total of 1,909 patients met the inclusion criteria, with 1,581 having complete treatment pathway data. The majority (87.4%) began treatment with fluconazole, followed by amphotericin B (6.5%) and echinocandins (2.3%); 11.2% underwent at least one treatment switch. The most common switches were fluconazole to posaconazole (2.2%) and amphotericin B to fluconazole (1.8%). Coccidioidal meningitis patients switched from fluconazole had increased rates of ICU admission and hospitalization but similar 1-year mortality compared to fluconazole monotherapy. Fluconazole remains the first-line antifungal for coccidioidomycosis, followed by amphotericin B. Most patients required solely fluconazole treatment. While many factors are involved in therapy choice, optimization of therapeutic strategies after initial fluconazole treatment may be necessary for the future, especially for severe disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora, Colorado, USA.
- Department of Clinical and Administrative Pharmacy, UGA College of Pharmacy, Albany, Georgia, USA.
- University of California-Davis, Medical Center, Sacramento, California, USA.
ORCID-Profile: Adeleine Tilley, Andrés F Henao-Martínez
Förderung
- F2G (F2G Ltd)
Zitieren
APA
Edwards, B., Ripperton, R., Tilley, A., Chastain, D. B., Thompson, G. R., & Henao-Martínez, A. F. (2025). Insights into current coccidioidomycosis therapeutic pathways. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01465-25
Vancouver
Edwards B, Ripperton R, Tilley A, Chastain DB, Thompson GR, Henao-Martínez AF. Insights into current coccidioidomycosis therapeutic pathways. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01465-25
BibTeX
@article{Edwards2025,
author = {Edwards, Brent and Ripperton, Rebecca and Tilley, Adeleine and Chastain, Daniel B and Thompson, George R and Henao-Martínez, Andrés F},
title = {Insights into current coccidioidomycosis therapeutic pathways},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01465-25}
}
EUVIMED